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1. Introduction
Malignant tumors of the colon and rectum represent a separate entity, due to their early
clinical  manifestation,  specific  methods  of  examination  and,  particularly,  due  to  treat‐
ment,  which  is  predominantly  based  on  the  need  for  conservation  of  the  sphincter
mechanism,  without  disturbing  the  oncological  principles  of  surgical  treatment  and the
necessary  radicalism.  In  spite  of  introduction  of  the  new  surgical  procedures,  and  the
significant improvements in radio, i.e. chemotherapy, the prognosis of these tumors remains
serious.
With regard to the histological structure, tumors can be:
1. Adenocarcinomas,
2. Carcinoids,
3. Lymphomas,
4. Gastrointestinal stromal tumors (GISTs),
5. Squamous cell carcinoma
6. Melanomas
7. Other (extremely rare forms of malignant tumors)
Adenocarcinomas account for 95-97% of all malignant tumors, while the remaining 3-5%
belongs  to,  so  called,  rare  tumors  of  colon  and  rectum.  The  annual  percent  change  in
incidence for each rare tumor increased significantly during the 10 years (range: 3.1–9.4%,
p<0.05), except squamous cell carcinoma (5.9%, p>0.05) [1]. With regard to the incidence,
all rare tumors of the large bowel can be divided into 2 groups:
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1. tumors with the incidence 0,1-2% and
2. rare tumors with the incidence <0,1%.
In the first group the most common ones are: carcinoids 1,8%, primary lymphomas 0,1-1%,
GISTs 0,9%, melanomas 0,5-1%, and squamous cell carcinoma 0,1% (without the anal canal).
The second group or extremely rare forms of malignant tumors consist of: teratoma, plasmo‐
cytoma, schwannomas, metastatic tumor. Literature data are limited and mostly concern series
of operated patients of some institutions or several published national studies, but there are
no randomized studies or meta-analyses which have higher degree of scientific verification
because these tumours are very rare [2].
The aims of studying the rare tumors of the colon and rectum are:
– determination of the incidence among population,
– determination of the clinical characteristics
– comparative analysis of the treatment outcome in different parts of the gastrointestinal tract
and
– overall and five-year survival of patients.
2. Carcinoids
Carcinoid tumors represents rare, slow growing tumors and they occur in 1,8% of all malignant
tumors of the large bowel. There is no clear predominance related to sex and, in the most of
cases, the patients are in their sixties or seventies. They originate from the enterochromaffin
(argentafil, Kulchitsky) cells, as a part of the diffuse endocrine system and they belong to the
group of neuroendocrine tumors, so called well-differentiated “NET’s”. They are also called
APUDomas, which is an abbreviation for “amine precursor uptake and decarboxylation”, due
to their ability to take over and decarboxylase amines, originally described by Pearse in 1969
[3]. They can occur in all parts of gastrointestinal tract as well as outside of the tract. Therefore
with regard to the place of occurrence and according to the division of the primitive intestine
during the embryological development, carcinoids are divided into:
1. foregut carcinoid tumors start in the lungs, bronchi, or stomach;
2. midgut carcinoid tumors start in the small intestine, appendix,or proximal large bowel;
3. hindgut carcinoid tumors start in the distal colon or rectum.
Data from literature indicate that the incidence of carcinoids in certain locations is different,
although it is considered to be most often localized on the appendix vermiformis, in about 40%
of cases, on ileum about 25%, on rectum 15-20% and on respiratory system around 10%. On
the other hand, the Japanese National Study has identified, in 90 057 operated patients during
the period of 15 years, 345 cases of carcinoids on the small and large bowel, out of which 0,9%
was localized on the ileum, 2,3% on the appendix, 8,2% on the colon and 88,6% on the rectum
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[1]. Their secretion is active and secrete around 30 vasoactive substances, the most important
of which are serotonin, histamine and substance P. In 1867, Langhans [1] first described a gut
carcinoid tumor, but the first detailed description of the tumor, similar to carcinoid, was given
by Lubrasch 1888, after performing the autopsy on two persons, previously treated due to
having multiple tumors of ileum. A German pathologist Oberndorfer first mentioned the term
“carcinoid” in 1907, while Siburg published the first data about the rectum carcinoid in 1929
[4-5]. The term “carcinoid” indicates that the tumor, according to some histological character‐
istics, is similar to carcinoma, but it behaves in a more benign way and less aggressive. They
have often been discovered accidently, during the colonoscopy, or by examination of the
clinical symptoms, such as rectoragia or diarrhea. During the primary diagnosing, 60-90% of
carcinoids are less than 1 cm of size.These tumors have a variable malignant potential, which
depends on: size, localization, depth of invasion and way of growth of the tumor itself.
According to the data from literature, the colon and rectum carcinoids less than 1 cm of size
have metastases in about 5,5% of cases. The bigger sized tumors, 1-1.9 cm, have metastasis
within the range of 4 to 30%, while those above 2 cm, within the range of 70-80%. With regard
to localization, the rectum carcinoids have metastasis in 18% on average, unlike the colon ones
in 60%, jejunoileal localization in 34%, stomach in 23% and lungs in 21% [2]. The depth of
invasion, particularly the tumors, which are less than 2 cm in size, represents a very important
predictive factor in the method and outcome of treatment. Invasion of muscularis propria and
lymphovascular, i.e. perineural invasion, anaplastic reaction, positive Ki-67 mutations and
frequent mitosis increase the risk of metastasis of tumors, which are less than 2 cm in size.
Macroscopically, these are small tumors in the nodular form, covered with the normal mucosa,
with intensive fibrosis of the intestine wall. Ulcerous forms with a tendency of bleeding, have
metastasis in larger percent and represent a significant risk factor. Histologically, the tumor
cells look similar, rounded or polygonal with expressed nucleus and acidophilic cytoplasmic
granules. Immunohistochemically, they show focal or diffuse existence of chromaganin A and/
or neuron-specific enolase, synaptophysina, CD 56 and pancreatic polypeptide. There is no
clear histological difference between benign and malignant large bowel carcinoids, except the
size of the tumor itself and invasion of muscularis proprie.
 
(a) (b) 
Figure 1. a) colon carcinoid (H&E 10x); b) colon carcinoid (chromogranin A 10x)
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2.1. Clinical presentation and diagnosis
The clinical presentation is characterized by the existence of symptoms resulting from the
secretion of different biochemical substances and growth of the tumor itself. Occasional
abdominal pains, followed by facial flushing, diarrhea, bronchospasm, arrhythmia, hyper‐
thermia, - blood pressure variations and vasomotor collapse, which, based on the intensity can
lead to a life dangerous condition, or so called “carcinoid crisis”. Various daily activities and
psychological conditions, such as alcohol drinking, emotional stress, increased body temper‐
ature and difficult defecation potentiate the intensity of symptoms.
The diagnosis of the large bowell carcinoids was usually made by detailed anamnesis and
clinical examination of the abdomen and digital rectal examination. Very often, it is an unclear
finding, due to the intact mucosa, so it is necessary to take biopsy from the part of the tumor
surface, as well as, from the deeper structures. It is also necessary to include a colonoscopy in
clinical examination, due to the possible existence of the synchronous lesion, and magnetic
resonance imaging or endoluminal ultrasound of the small pelvis, because of the pre-operative
staging. The examination of the liver metastatsis, should be completed with an ultra-sound
and CT scan. The modern diagnostics of carcinoids understands also the, so called, functional
or biochemical examinations based on taking over of the certain substances by the tumor cells,
which makes them different from the normal tissue. The biochemical properties of carcinoid
tumors reflect the presence of neurosecretory granules. They are classified as biochemically
typical or atypical based on the presence of high levels of serotonin in so-called typical tumors.
The best known metabolite of serotonin in carcinoid tumors is 5-HIAA( hydroxyl indole acetic
acid). In a 24-hour sample, the urinary level of 5-HIAA is the test most commonly used in the
endocrine work-up of carcinoid tumors. Despite its popularity, it lacks the sensitivity and
specificity for the diagnosis of carcinoid tumors because 5-HIAA may not be elevated in
atypical carcinoids and can be elevated in other conditions such as tropical sprue, celiac
disease, Whipple's disease, and small bowel obstruction, and can be caused by ingestion of
food high in serotonin, or certain medications.
Although a number of other tumor markers have been investigated for carcinoid tumor
overproduction, serum analysis of chromogranin A, a glycoprotein that is secreted with other
hormones by neuroendocrine tumors, appears to be the most promising, with specificity
approaching 95% and sensitivity for carcinoid tumors approaching 80 percent. A 40 percent
false-positive rate has been seen in patients with multiple myeloma[6].
For this purpose, the scintigraphy of the somatostin receptors on the surface of tumor cells is
applied, or SRS and PET scan, which uses a metabolic taking over of FDG Fluorin- 18 fluoro‐
deoxyglucose, by the tumor cells. The results of the research indicate that, Octreoscan is the
most optimal for identification of the primary tumor and existence of the positive lymph nodes,
while in the case of distant metastasis, it is CT or NMR. Within the frame of the biochemical
analyses, in case of doubt that there is a carcinoid present, it is necessary to determine the level
of 5 hydroxy-indole acetic acid in urine.
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2.2. Treatment
The treatment of the colon carcinoid can be divided into two groups:
a. minimally invasive procedure
b. laparatomy
c. Minimally invasive procedure includes several types of interventions:
– endoscopic mucosectomy or submucosectomy
– transanal tumor extirpation
– TEM (transanal endoscopic microsurgery)
– laparoscopic resections of colon and rectum
Endoscopic mucosectomy or submucosectomy represent one of the possible methods in the
conditions of the initial stadium of disease, without penetration into muscularis mucosae, and
up to 1 cm of size. The literature data show that endoscopic mucosetomy or submucosetomy
are performed in 54% of patients suffering from rectum carcinoid, transanal extirpation of
tumor /TEM in 27% of the operated patients, on one hand, as well as in 6% of patients treated
by the invasive procedure, on the other [7-9].
The results of the treatment indicate that, in patients treated by the endoscopic methods, in
83% of cases, it was about the positive limits (R1 status), in 16% it was the residual tumor (R2
status) with 2% of acute complications in terms of the occurrence of post-operative bleeding.
In 12 patients (14%), a sub-mucosectomy was done, with 42% of the positive margins present.
The advantage of the endoscopic approach is a minimally invasive procedure, faster recovery
of a patient and smaller operative trauma, but there are also disadvantages in terms of the high
percent of R1 or R2 procedure, (positive margins or residual tumor).
Transanal exstirpation/TEM is indicated in the conditions of rectal carcinoid invasion to the
submucose and muscularis proprie. They are mainly performed after the unsuccessful,
previously done mucosectomy i.e. sub-mucosectomy. The results of treatment indicate that in
43% of the operated patients, RO resection was done, while in 52% of cases R1, i.e. R2 resection
was done. The post-operative complications occurred in about 9% of patients. The disadvant‐
age of the procedure is still a high percentage of R1 and R2 operations.
Laparoscopic resections of colon and rectum represent a trend in the modern colorectal
surgery, with all characteristics of the minimally invasive procedure. It is indicated in tumors,
which spread to the structures deeper than lamina muscularis mucosa (T2 stadium), most often
to the upper third of rectum, but the other parts of rectum as well, where performing the
endoscopic procedure would lead to a high percent of R1 and R2 operations.
2.2.1. Laparatomy
– resection of colon (according to the type of segmental or right/left hemicolectomies)
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– (resections of rectum with different forms of reconstructions T-T anastomosis, L-T anasto‐
mosis, colonic J pouch, etc.)
– incontinence operations (abdominoperineal amputation of rectum, etc.)
– in case of inoperability of tumor, the performance of colostomy.
Laparotomy is indicated in carcinoids of greater median size, so-called bulky tumors, with
infiltration to the surrounding organs, as well as, with the potential risk of the colon obstruc‐
tion. In relation to the outcome of treatment, the resection procedures are loaded with a higher
percent of the local recurrence rate, which is explained by the existence of the more invasive
and bigger tumors, treated in this way [10-13].
Systemic therapy in carcinoid treatment has two aims
– to reduce intensity of the systemic effects of disease and
– treatment of metastasis.
Reducing intensity of the systemic effects means the use of various medicaments, such as: H2
blockers, Phenothiazin, corticosteroids, serotonin blockers serotonin, bronchodilators etc. The
analogues of Somatostatin have a significant effect that, by blocking the receptors reduce the
production and systemic effects, primarily the intensity of flushing and diarrhea, in 80% of
patients.
Staging system Colon carcinoids
% patien. 5-year surv.%
Rectal carcinoids
% patient. 5-year surv.%
I 13 97 83 97
II 32 69 6,5 84
III 12 21 2,8 27
IV 43 17 7,4 20
N 0 52 96
1 48 4
M 0 76 97,6
1 24 2,4
Table 1. Staging system and 5- year survival rate [14-16]
In treatment of metastasis, the effect of chemotherapy application ( 5-fluorouracil, strreptozo‐
tocin, doxorubicin,, etoposide, cisplatin, carboplatin, etc. ) is insignificant, with a clinical
response ( Response Rate- RR) from 0 to 30%. In some cases, Interferon is used, in duration of
up to 2,5 years, but due the numerous unfavorable effects, its use is limited [6].
The prognosis of the disease, depending on TNM stadium. A search of 15,983 patients with
carcinoid tumors from the National Cancer Institute's SEER (Surveillance Epidemiology and
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End Results) database identified 2459 with colon tumors and 4701 patients with rectal carcinoid
tumors from 1973 to 2004. Patients were analyzed according to various clinicopathologic
factors and a tumor (T1, T2, T3), lymph node (N0, N1), and metastasis (M0, M1) staging system
was created according to these parameters. Results is shown in Table 1.
3. Primary non-Hodgkin lymphomas
Lymphomas of colon and rectum are the rare tumors that make 1,4% of human lymphomas,
10-20% of gastrointestinal lymphomas, 0,2-0,6% of all malignant tumors of colon, that is, 0,1-1%
of all tumors of the large bowel. According to the incidence in the gastrointestinal system in
adults, they take a third place, following the stomach and small intestine, unlike with the age
of up to seventeen, where the intestinal localization is predominant. In relation to the incidence
of all malignant colon and rectum diseases, they take a third place, following adenocarcinoma
and carcinoids [17,18]. The predilection places of occurrence are cecum and rectum, due to
large amount of lymph tissue in these regions of the large bowel.
Figure 2. Primary non-Hodgkin lymphoma of the cekum
It occurs more often in male patients, older than 50. With regard to the degree of spreading,
diseases can be: primary (localized) and secondary (diffuse form). The primary lymphomas of
the large bowel are characterized by the existence of the so-called Dawson’s criteria [19]:
1. no palpable, superficial lymph nodes at presentation;l
2. no enlarged mediastinal lymph nodes on chest x-ray;
3. normal range for white blood cell count including total and differential
4. at surgery, only the regional lymph nodes are involved;
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5. the liver and spleen are without disease
Primary lymphoma of the colon is a predominantly extranodal form of non-Hodgkin lym‐
phoma, while Hodgkin type is much rarer, present in less than 5% of all patients autopsied
due to this disease [20-22]. Devin and his coworkers from the Mayo Clinic, published the largest
study of patients with rectum lymphomas,which shows that, out of 61 patients treated in the
period of 27 years, 49 of them had a diffuse form and only 12 had a localized disease [23]. The
tumors usually have a form of polypoid and ulceriform mass, and sometimes, they form
excrescent on mucosa, similar to multiple adenomatous polyposis.
Etiological factors in formation of the large bowel lymphoma are unknown, as well as for the
other types of malignant diseases. However, the higher incidence was noticed in the conditions
of immunosuppression, such as the inflammatory disease – ulcerative colitis, HIV virus
infections and conditions after organ transplantations, although there are no clear scientific
proofs about the connections among these diseases.
More than two-thirds of intestinal lymphomas are supposed to be of B cell lineage, while T
cell intestinal lymphomas are rather infrequent and often multifocal and most frequently
localized in the small bowel. In relation to the histological type of B cell, non-Hodgkin
lymphomas can be: diffuse B cell type, MALT lymphoma, mantle type, Burkitt type and
follicular lymphoma. The incidence of some histopathological forms differs from study to
study, so Anderson and his associates presented the data of the, so-called, International Study
Group about Lymphomas, which included 1378 patients from 8 different cities from 4
continents. Out of the total number of the histopathological findings, in 80% of cases B-cell
lymphoma was diagnosed, where the most common form was the one with the large cells,
while the other forms, such as mantle, Burkitt and MALT types were significantly rare. In
relation to the histological grades, in 75% of tumors, a moderate and intermediately type of
diffuse lymphoma of the large cells was established [24-27].
Figure 3. Mantle type of primary non-Hodgkin lymphoma
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The degree of disease spreading to the surrounding structures was the best presented by the,
so-called, Ann-Arbor staging, modification according to Musshoffu [28,29]. The aim of the
successful treatment is the early detection of the disease in IE or IIE stage where still there is
a possibility of curative resection. The data from literature are significantly different in relation
to the stage of a disease in treated patients, which is a consequence of the various criteria
according to which the patients were included into the study, different methodologies of
performance and the level of health culture among the tested population.
Stage Characteristics
IE Limited to the colonic/rectal wall
IIE 1 Involvement of paracolic lymph nodes
IIE 2 Involvement of intermedial lymph nodes.
III Involvement of the large bowel and lymph nodes on bothsides of diaphragm
IV Involvement of distant organs (large bowel and one ormore extralymphatic organs or tissue)
Table 2. Ann-Arbor staging- Musshoff modifications of primary colorectal lymphoma[29].
3.1. Clinical presentation and diagnosis
The clinical presentation is characterized by the existence of rectoragia and the changed bowel
habits. By analyzing the symptoms of the disease, Cho and his associates, presented the study
data, which showed that, out of 23 patients, 56% had a non-specific symptoms, abdominal pain
and weight loss or anorexia, that is, 35% the of tested patients were operated in the advanced
stage of the disease [30]. The data from the research made by Fan and associates, showed that,
out of 37 tested patients, 59% had only abdominal pain and 75,7% were operated in the stage
of the disease where positive lymphoma nodes were present in the mesenterium of colon and
mesorectum. The specific symptoms, such as bleeding per rectum, were present in only 12,5%
of patients [17]. Non-specificity of symptoms often postpones timely visit to a doctor and
timely diagnosing, which leads to a much higher incidence of the advanced stages of the
disease. A special problem is primary colorectal lymphomas - present as surgical emergency,
caused by tumors of the IIIE and IVE stages[31]. Surgical emergencies, caused by the obstruc‐
tion of the large bowel, or perforation, initiate a need for urgent surgical intervention, which
leads to significantly higher rate of mortality of 58% and more frequent disease recurrence
[32-36]. The diagnosis can be made - by taking the anamnestic data and clinical examination
including digito rectal examination and colonoscopy with biopsy. There are data from
literature, which show that it is not always possible to establish the diagnosis by endoscopic
procedures, due to inadequately made biopsy of the tumor, as well as the need for timely
performance of an adequate immunohistochemical staining during histopathological exami‐
nation, which is done by a pathologist. It very often leads to inability to give correct interpre‐
tation of the pathologic finding [37].
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3.2. Treatment
Modern treatment of the primary lymphoma of colon and rectum implies a multi-modal
approach, that is, a surgical intervention, chemotherapy and radiotherapy in selected cases.
Beside the doubtless improvements achieved in surgical technique, as well as in anesthesiology
and chemotherapy, during the last three decades, there is still a low level of the five-year
survival among the operated patients, which is 42% [29, 37]. The treatment of the large bowel
Non-Hodgkin lymphoma is characterized by the existence of different attitudes about it, from
applying only chemo and radiotherapy on one side, to the performance of surgical procedures,
on the other. Bilsel and his associates published a review of the case from 2005, which gave a
complete clinical response of the primary rectal lymphoma, after the treatment with chemo
and radiotherapy [24]. The other authors also presented similar data [ 38,39]. Pricolo and his
associates, in their analysis of the case presentation from 2002, describe the treatment of rectum
lymphoma using the resection procedures and then chemo and radio therapy, while Shimono
from Japan recommends a pre-operative radiotherapy first, and then a surgical intervention
[40,41]. Regarding the type of operation, there are recommendations that, with small dimen‐
sion primary rectal lymphoma and low malignant potential – MALT or mantle type lympho‐
ma, it is enough to perform a limited resection or transanal extirpation of tumor [42,43]. The
differences in attitude are the consequence of the results achieved based on the presentations
of cases or studies about a small number of patients and a heterogeneous groups of the treated
tumors, in various stages of the disease, with different histopathological diagnosis etc.
Nevertheless, based on the modest experience of the authors, the resection of the large bowel
is recommended whenever possible, together with neo or adjuvant therapy [44, 45].
4. GISTs
Gastrointestinal stromal tumors or, shortly GISTs, are the most common mesenchymal tumors,
which are characterized by positive c-KIT, that is, CD117, CD 34 antigens, and they make
0,1-1% of all gastrointestinal tract tumors. They occur most commonly in the stomach 60-70%
and small intestine 20-25%, while they are the least present in the large bowel, around 5%, and
0,9% of all tumors in the rectum. In relation to the incidence of occurrence only in the large
bowel, they occur in 80% of all patients in the rectum, while in 20% of cases it is in the colon.
They occur in middle-aged persons between 40-60 and between both sexes equally, with the
incidence of 6,8 / 1 000 000 [46].
At the beginning of XXth century, Theodor Bilroth provided the first descriptions of the stromal
tumors. However, the term “stromal tumor” was introduced bay Mazur and Clark only in
1983, following the development of immunohistochemistry. One year later, in 1984, Henry
Appelman introduced the term "GIST-gastrointestinal stromal tumors" for the first time, while
Kindblom and his associates proved that GISTs originate from the interstitial Cajal cells, which
represent the so called, pace maker cells of the gastrointestinal tract. Due to the similar
structural and immunohistochemical characteristics of GISTs and Cajal cells, many authors
are of the opinion that they originate from the same mesenchimal cell [45]. Invasiveness, or
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the metastasis risk assessment of the GISTs on various locations, determined by the size of
tumor and mitotic index, as shown in table 4 [47].
Mitotic count Size Gastric GIST Duodenal GIST Jejunal & ileal GIST Rectal GIST
≤5/50
<2 cm 0% 0% 0% 0%
>2 ≤5 1.9% 8.3% 4.3% 8.5%
>5 ≤10 3.6% 34% 24% 57%
>10 12% 52%
>5/50
≤2 0% N/A 50% 54%
>2 ≤5 16% 50% 73% 52%
>5 ≤10 55% 86% 85% 71%
>10 86% 90%
Table 3. Metastasis risk assessment of GISTs in different parts of GI tract [48].
4.1. Clinical presentation and diagnosis
GISTs are symptomatic in about 70%, - in about 10% asymptomatic and in 20% they are
discovered during the autopsy, which shows that 1/3 of the large bowel stromal tumors are
clinically completely silent. The symptomatology is very similar to the other colon tumors, and
is characterized by hematochezia, abdominal or rectal pain, occurrence of complete rectum
prolapse etc.[49]. Depending on the tumor size, it is possible to get the clinical presentation of
the obstruction or ileus, caused by the growth of GISTs. The diagnosis - can be made by taking
the anamnestic data, clinical examination including a digital rectal exam, which should be
completed with rectoscopy, colonoscopy, endorectal ultrasound and NMR. It is necessary to
do a biopsy of tumor with immunohistochemical analysis, for definite confirmation of the GIST
existence in the large bowel. In the case of any doubt that there is metastasis in the liver, it is
also necessary to perform the ultrasound and CT scan, within the complete staging of tumor.
PET scan is indicated in the operated patients in order to follow up.
4.2. Treatment
Surgical intervention is a method of choice in treatment of large bowel GISTs, and is applied
in the following cases:
1. Primary disease;
2. Metastatic diseases
3. Recurrence
The main aims of surgical treatment of the primary disease are the complete resection, so-called
R0 resection and preservation of the tumor pseudocapsule, without wide resection margins
and lymphadenectomy. This is very important in treatment of the rectum GISTs, due to the
Rare Tumors of the Colon and Rectum
http://dx.doi.org/10.5772/56937
263
aims of sphincter saving procedure and improve the patient’s quality of life. With regard to
the size and localization of the large bowel stromal tumors, it is possible to use various surgical
procedures: segmental resection, local excision, anterior and abdominoperineal resection. The
performance of the anterior resection (high or low), means the observance of the partial or total
mesorectal excision principles, in order to prevent sacral nerves injury, bleeding or local
recurrence.
Figure 4. Rectal GIST
When GIST adheres to contiguous organs, consideration should be given to an en bloc
resection. The modern aspects of the GISTs treatment also mean the use of Imatinib, a
medicament, which revolutionary contributed to the significantly better results in treatment
in GISTs. Joensuua, Heinrick van Oosterona and Tuveson made the first reports about the use
of Imatinib in 2001. An immediate cause for the invention of this medicament was the discovery
of Hirot about the existence of the abnormal activation of KIT oncoprotein or transmembrane
receptor tyrosine kinase and the following mutation of C-kit gene, with exceptional cellular
proliferation. Imatinib selectively inhibits the receptors of the transmembrane tyrosin kinese,
thus blocking the abnormal growth of tumor. Van Oosteron and his associates published the
results from 70% of clinical responses in KIT-positive metastatic GISTs [50,51]. Primary
unresectable GISTs of the large bowel are initially treated with Imatinib, with an aim to reduce
the size of a tumor – “downsizing”. In the case of the existence of a metastatic disease, a non-
adjuvant use of Imanitib is indicated, in order to secure good clinical response, meaning a
disease without progression, with the possibility of performing R0 resection [52]. When there
is a small volume metastasis in liver, some authors recommend the simultaneous resection of
the large bowel and liver, and then the application of Imatinib[53]. Distant metastasis occur
on the liver in over 50%, and they are treated with the initial application of Imatinib, followed
by the various resection procedures.
The treatment of GISTs using chemotherapy has a minimum effect, RR<10%, and has no
significance for the overall survival, as well as the application of radiotherapy, since the tumor
is radio resistant.
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4.3. Treatment outcomes
The outcome of the large bowel GISTs treatment is troubled with a high percentage of local
and distant recurrences, so after the R0 resection, it occurs in 45-50% of cases, 20-25 months
after the surgical intervention. The average five-year survival rate is 50%, 73% after the R0 and
in 26% after R1 and R2 resections. In the case of the advanced disease with local recurrence
and metastatic disease, a five-year survival rate is 28-35% [54].
5. Squamous cell carcinoma
Squamous cell Carcinoma of the large bowel is a very rare disease, unlike its localizations on
the esophagus and the anal canal. The data from literature are based on the reviews of the
clinical cases and series with a small number of patients. Schmidtmann first described the
squamous cell carcinoma of the large bowel, actually cecum in 1919, and Reiford described the
same disease on the rectum in 1933. Currently, there are about 100 cases of the squamous cell
carcinoma of the large bowel described in literature, and the incidence of the disease is 0,1-0,25
on 1000 patients suffering from the colorectal carcinoma [55].
Due to a very rare occurrence of the tumor, there is a lack of prospective studies, or meta
analyses, which would offer data about the demographic characteristics of the patients, risk
factors, the nature of the disease behavior, as well as the optimal treatment.It mainly occurs in
patients of the average age of 60, more often among women 66% than among men 34%
[56].Etiology of the occurrence of colorectal squamous cell carcinoma is still unknown, as well
as of the other kinds of malignant diseases, although there are several theories trying to explain
the formation of this neoplasm:
– The influence of differentiation of stem cells,
– Squamous metaplasia at the place of existence of colorectal adenoma,
– Proliferation of uncommitted mucosal basal cells into squamous cells which subsequently
undergo a malignant transformation
– Oncogenic influence of the chronicle kidney insufficiency, as well as, the application of the
immunosuppressive therapy in terms of development of some cancerous viruses or oncogenic
differentiation of the stem cells,
– Special influences of irradiation, colocutaneous fistula, ulcerous colitis, Entamoeba histoli‐
tyca colitis, homosexuality, immunosuppression, schistosomiasis, and still unclear influence
of HIV (human papilloma viruses types 16, 18, 31, 33) [57- 59].
5.1. Clinical presentation and diagnosis
The symptoms of the disease are very similar to the symptoms of colon carcinoma, such as
bleeding, abdominal pain, change in bowel habits with the episodes of diarrhea and obstipa‐
tion and weight loss.The diagnosis is established by taking the anamnestic data, clinical
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examination including digital rectal exam, which should be completed with rectoscopy,
colonoscopy, MSCT, endorectal ultrasound andd NMR.Williams and his associates published
the following criteria for diagnosing the squamous cell carcinoma of the large bowel, in 1979:
1. non-existence of the squamous cell carcinoma and its metastasis on the other locations
(particularly the skin),
2. careful anoscopy and rectoscopy in order to exclude the existence proximal extension of
anal squamous cell carcinoma,
3. non-existence of a fistulous tract lined by squamous cells [55, 58].
These criteria should be completed with the excision biopsy of tumor, as well as, the PH, or
immunohistochemical confirmation (presence of cytokeratin CAM 5.2, AE1/AE3 i 34B12. CAM
5.2). Sub-mucous localizations of the squamous cell carcinoma represent a separate problem,
due to difficult identification during standard examinations, so, in these cases, it is recom‐
mended to use endoluminal ultrasound guided needle biopsy of tumor. Determination of
values of the tumor markers represents one of the possible auxiliary diagnostic procedures for
determination of the disease, under the condition that the marker is specific for a particular
tumor. In the case of the squamous cell carcinoma of the colon and rectum, there are no specific
tumor markers, so those, usually used for the anal squamous cell carcinoma or for the so called
layer plate cells of carcinoma antigen ( Squamous cell carcinoma antigen "-SCC Ag)", are used.
According to the opinions of some authors, SCC Ag is not specific for the initial diagnosis, but
for the follow up of the occurance of local and distant recurrence after treatment [60].
5.2. Treatment
Surgical intervention is a method of choice in treatment of the squamous cell carcinoma of the
large bowel. The type of surgical intervention depends on the size of tumor, its localization,
depth of invasion into the colon wall, presence of local and distant metastasis, BMI (Body Mass
Index), general condition of the patient and presence of comorbidity. The types of surgical
intervention are similar to those used with the colon carcinoma: endoscopic mucosa/sub-
mucosa resection, segmental or hemi colectomy, local excision, resection procedures on the
rectum, as well as abdominoperineal amputation of the rectum. Endoscopic mucosa/sub-
mucosa resection is applied based on the experience acquired in treatment of adenocarcinoma,
and is indicated in patients with superficial tumors – T1 stage and with an expressed comor‐
bidity. Endoscopic mucosa/sub-mucosa resection, local excision (trans-anal or trans-anal
endoscopic microsurgery-TEM) is a method of choice with T1 stage of the disease, which means
a tumor spreading to mucosa/sub-mucosa. There are some dilemmas about the type of
treatment in T2 stage (spreading to muscularis proprie), because after application of the local
excision, a recurrence rate is present in 20% of the operated patients. In these cases, it is
necessary to make a good pre-operative staging of tumor in relation to the existence of the
positive lymph nodes and the range of spreading to the large bowel wall.In the cases of the
transmural spreading to the wall, up to the pericolic/rectal fat tissue – T3 stage, as well as the
infiltration into the surrounding organs T4-stage, there are dilemmas whether it is better to do
a surgical intervention first, and then the chemotherapy, or vice versa. The researches, which
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were made based on the application of the identical treatment protocol in anal squamous cell
carcinoma - (combination of the chemo and radio therapy 5-FU +mitomycin-C and radio 45
Gy), did not give the expected results in localization of the proximal parts of the rectum and
colon. There are data in literature, which recommend only application of the chemo and radio
therapy, as well as, the simultaneous chemo-radiation. However, the majority of authors agree
that, for the time being and based on the experiences acquired in treatment of a small number
of patients, the optimal therapy means surgical intervention and the adjuvant chemo radiation
[52]. Surgical treatment of the advanced disease means the application of the resection
procedures (colectomy, high and low resection of rectum) and abdominoperineal amputations
of rectum. The resections of rectum, as a sphincter preserving operation, enable better quality
of life of the patient on one hand, and compliance with the oncological principles on the other.
Regardless of the advantages of the resection procedures in relation to the amputation surgery
of rectum, the data from literature show that Miles’s operation has been performed twice as
much in treatment of the squamous cell carcinoma of rectum, which has been explained by a
large number of advanced tumors at the time of diagnosing [61].
The disease prognosis is based on determination of the TNM stage, the most important
prognostic factor, identical to the one in anal squamous cell carcinoma. The TNM stage is
shown in Table 4.
Stadium T N M
0 Tis N0 M0
I T1 N0 M0
T2 N0 M0
IIA T3 N0 M0
IIB T4 N0 M0
IIIA T1-T2 N1 M0
IIIB T3-T4 N1 M0
IIIC Any T N2 M0
IV Any T Any N M1
Table 4. TNM staging system of squamous cell carcinoma of the large bowel [56].
By comparing the disease prognosis from adenocarcinoma of the colon and rectum of the same
stage, it has been established that stages of the disease I and II have a similar prognosis, unlike
the advanced ones (stages III and IV), where squamous cell carcinoma has worse prognosis.
The average five-year survival is 32%, with variations, which are related to the certain stages:
Dukes B 50%, Dukes C 33% & Dukes D 0%. Application of the adjuvant therapy improves the
overall survival of a patient, on one hand, while the pre-operative radiotherapy increases the
percent of the sphincter preserving operation, on the other [58,59].
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6. Melanoma
Melanoma of the gastrointestinal tract is a rare mucosal melanoma with a particularly
aggressive biology compared with cutaneous one of equal stage. They most often occur as a
metastatic tumor, while the primary localization is rare and possible in esophagus, stomach,
small intestine and anorectum, that is, at the places where melanocyte normally exist. The
colon melanoma is an extremely rare tumor with regard to the fact that, embryologically,
melanocytes do not exist in this part of colon and that, up to now, only 12 cases have been
describes in the English literature. There are several theories, which describe the formation of
the colon melanoma: relation to neural crest cells, model of tumor regression and ectodermal
differentiation, but none of them has been completely proved so far. Localization in the
anorectum takes the third place regarding the incidence of localization, behind the rest of skin
and eyes surfaces and it makes 1-1,5% of all melanomas in the human body, and 3-15% of all
tumors of the colon and rectum [62,63]. Moore described it for the first time in 1857 and, until
now, the total of 500 cases was described in the literature. The most often it occurs on the skin,
under the dental line, and rarely at the level of cuboidal epithelium of the transition zone and
mucosae of the distal rectum. It is more common in women (twice as much than in men),
between 60 and 70 years of age [64]. The melanoma represents a disease of the neuroectodermal
origin, which the most often originates from melanocytes and nevus cells of the basal layer of
epidermis, and significantly less from mucosa. It has an extremely worse long-term prognosis,
because of the disease discovery in the advanced stage, mainly with metastasis in the inguinal
nodes. Beside the lymhogenous dissemination, spreading is possible by the local ingrowth and
in hematogenous way. The local spread is according to the radial (horizontal) and vertical
growth. Radial growth means circular spreading around the primary tumor, through the
epithelium of mucosa and the superficial layers of sub-mucosa, without tendency of metasta‐
sizing. Vertical growth means penetration into the deeper layers of the colon wall, with
simultaneous metastasizing. Determination of level of the vertical tumor growth, i.e. involve‐
ment of the colon and rectum wall layers, is essential for the choice of surgical intervention.
The most important roles here have the MSCT (multi-slice scanner), NMR (magnetic reso‐
nance) and endoluminal ultrasound. Hematogenous dissemination occurs by penetration of
the melanoma cells into the blood vessels, with further spreading to the whole body. About
30% of patients, at the moment of diagnosing, are considered to have a disseminated process,
while only 17% of the operated ones have a five-year survival. [65,66]. It differs from skin
melanoma in the way that 25% of tumors do not contain a pigment of the so called “coloured”
tumor, and because ultraviolet radiation is a factor of protection, not a risk. In case of existence
of the pigment tumor of the rectum, the macroscopic appearance is very similar to thrombosed
external and prolapsing internal hemorrhoids (see figure 5), which can mislead a doctor in
setting a diagnosis[67,68].
The symptoms of the disease are different, but the most common ones are the abdominal pain,
weight loss and bleeding.The diagnosis of the disease implies to detailed anamnesis, physical
examination with special reference to inspection of all parts of skin and eyes, as the most
common primary localizations, as well as, taking biochemical laboratory analyses, digito rectal
examination, colonoscopy, barium enema, multi-slice scanner (MSCT), magnetic resonance
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(NMR), endoluminal ultrasound and tumor biopsy with pathohistological and immunohis‐
tochemical processing. Special attention should be paid to the examination of certain groups
of lymph nodes, depending on the primary tumor localization. Taking into account the results
made by Kalid and his associates, the most often localization of the primary colon melanoma
is cekum ascedens and transversum, while with the metastatic melanoma these are the
ascendant and descendant parts of colon [62]. Curative treatment of the large bowel melanoma
is exclusively surgical. The main aim of the treatment is to achieve a compromise between the
necessity to apply a radical oncological treatment and a need to preserve the patient’s quality
of living. The contemporary approach to treatment of the primary colon and rectum melanoma
implies to the performance of surgical interventions, such as:
a. colectomy with wide excisional margins (partial, hemi-colectomy, subtotal and total)
b. trans-anal wide local excision with preservation of the anal sphincter (in the case of the
initial stage of the rectum tumor)
c. extensive surgeries according to the type of the rectum resection or abdominoperineal
amputation.
There are numerous dilemmas about which type of surgical intervention to be applied in
certain stages of the disease. The supporters of radical treatment recommend the resection or
rectum abdominoperineal amputation, depending on the localization, with dissection of both
inguinal regions, stating the following advantages:
– possibility of the detailed exploration of the abdomen and the eventual discovery of distant
metastasis;
– lower percent of the local recurrence rate [69].
On the other hand, some authors recommend a wide local excision of tumor with preservation
of the sphincter mechanism, for the following reasons:
– absence of definitive stoma,
– similar five-year survival [70,71].
 
(a) (b) 
Figure 5. a). Prolapsed melanoma recti; b). Histopathological finding of melanoma recti (H&E 40x)
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The authors from MD Anderson Cancer Center present 20-year experience with treatment of
54 patients with localized anorectal melanoma, demonstrating that combined surgical wide
local excision and adjuvant radotherapy provides good local disease control with acceptable
side effects [72].The existence of such different attitudes in literature is a consequence of,
primarily, uneven criteria of the researches made, comparison of different localizations of the
anorectal melanoma and stage of the disease. The most significant parameter, based on which
a decision about the type of surgical intervention is made, is the thickness of tumor. According
to Weynadt and his associates, indication for a wide local excision are melanomas up to 4 mm
thick, with the limits of excision up to 2 cm from the primary tumor, without involvement of
sphincter, while the extensive surgeries on the rectum are recommended for the melanomas
over 4 mm thick [73].In relation to the adjuvant therapy, melanomas are considered hemi
resistant tumors, so certain cytostatic medicaments have an effect in 10-25% of the treated ones.
The most often used are: dacarbazin, temozolamid, cisplatin, carboplatin, nitrosoureas.The
latest research showed that determination of biological markers RAS/RAF/MEK/ERK,
represent a significant indicator of the cell growth intensity degree, as well as, the invasion
and survival [62]. The adjuvant therapy of anorectum melanoma is not very much successful
because all these tumors are radio resistant and scarcely responsive to chemotherapy[74,75].
6. Extremely rare tumors
Other tumors include an extremely rare malignant diseases of the large bowel: primary
teratomas, extramedullary plasmacytomas, schwannomas and metastasis of distant tumors.
Primary teratomas of the large bowel are very rare diseases and, there are only about 50 cases
published in literature until now, mainly the ones in the rectum and in the form of clinical
presentation. It occurs more often in women at the average age of 42,5. They are considered to
originate as consequence of the ectopic development of the so-called “captured” ectodermal
tissue although, in their composition, some structures of mesodermal endodermal origin are
possible. Histologically, it is composed of the stratified squamous epithelia, fat cells, hair
follicle, cartilage and, partially glandular tissue. They are usually benign tumors, however
some malignant transformations are also possible, which create a need for the total elimination
of tumor, due to compliance with the oncological principles. Data from literature indicate that
teratomas usually occur in the ovary, testicles, mediastinum and the middle lines such as
sacrococcygeal region, while they occur less frequently in the gastrointestinal tract (rectum,
sigmoid part of colon, appendix and terminal ileum) [76]. The rectal teratomas usually have a
polypoid cystic form, with protrusion into the lumen area. The solitary cysts are mainly
present, filled in with sebaceous whitish liquid into which the sebaceous glands, hair follicles
and teeth are immersed. Beside the cystic form, the existence of the solid tumors is possible,
which indicates a mature form of the teratoma.
The clinical presentation is characterized by the presence of pain during defecation, bleeding
and change in bowel habits. The diagnosis is established by the anamnesis and digital rectal
examination, which confirms the existence of the polypoid tumor mass of mainly smooth edges
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and a pedicle. The cases of rupture of the ovarian teratoma into the rectal lumen are described,
with the similar difficulties. The additional diagnostic procedures, such as the endoluminal
ultrasound, multi-slice scanner and NMR give the additional information about the extensity
of the tumor itself, as well as, the estimation of operability. Some malignant transformations
of teratomas with a tendency of creating squamous cell carcinoma are possible, and due to
this, it is not advisable to perform the transanal punctuation because of the danger of malignant
cells spreading, on one hand, and the potential infection, on the other. The method of choice
in the treatment is the complete elimination of the cystic tumor.
The most frequent form of plasma cell neoplasm is a multiple myeloma. Out of the total
number of all multiple myeloma, only 2% are the so-called extramedullary plasmacytoma.
More the 75% of extramedullary plasmacytoma occur in the upper part of the respiratory
system, while the most common places of occurence in the gastrointestinal tract are the
stomach and small intestine. Until now, 22 cases of the occurence of extramedulllary plasma‐
cytoma in the colon, have been reported, where the average age of patients was around 52,3.
The most frequent localization on the large bowel are the cecum with 36,4% and rectum with
22,7%. It is essential to make a differential diagnosis differentiation between the primary and
secondary plasmacytoma, that is, the metastasis of the multiple myeloma. It is achieved by
determination of the Bence-Jones proteins in urine, by serum electrophoresis, as well as, the
immunohistochemical finding of the collections of monoclonal plasma cells.
The treatment involves the application of:
– surgical intervention in 81,8% of cases,
– radio-therapy in 9% of cases,
– combined application of surgical intervention and radio-therapy in 4,5% of cases [77,78].
Schwannomas originate from Schwann cells, which form neural sheath and belong to the
group of stromal tumors. In the gastrointestinal tract, they most frequently appear in the
stomach, while the primary Schwannomas of the large bowel are extremely rare and, until to
now, only 39 clinical cases have been reported. They mainly occur in older patients around 65
years of age, of both sexes equally. They grow slowly and there is a large number of patients
who do not have any symptoms at the moment of diagnosing. The symptoms occur depending
on the size and localization of tumor, but vague pain in the abdomen, bleeding and change of
bowel habitus mainly manifest them. The pre-operative diagnosing, using the standard
procedures such as anamnesis, physical examination, colonoscopy MSCT, NMR and endolu‐
minal ultrasound, is possible in determination of the tumor mass, but not the type and kind
of tumor because it resembles to the GIST tumors of the colon. The most accurate diagnosis
implies the elimination of tumor as a whole, with pathohistologic and immunohistochemical
analyisis. It is also difficult to differentiate it from GISTs in respect of immunohistochemical
analyisis and some authors classify it the sub-group of GISTs, such as GANT tumors, i.e.
gastrointestinal autonomous nerve tumors [79].
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7. Metastases in the colon and rectum from the distant tumors
The metastasis of distant primary tumors rarely spread to the large bowel, and it is usually
related to the carcinoma of the surrounding organs (stomach, pancreas, ovarian etc.) which,
due to their growth and size, spread to the surrounding parts of colon, or “fall” on the
intraperitoneal rectum with secondary infiltration. The degree of the tumor spreading depends
on the length of the primary tumor existence and the histologic type, although the literature
data indicate that serosa is infiltrated in 28%, muscles’ layer in 31% and mucosa in 14% of
patients. The expansion of the prostate cancer is possible, with perforation to Denonvilliers
fascia and the secondary spreading to the rectum, according to the type of circumferential, i.e.
annular stenosis, without spreading to mucosa in men, as well as the carcinoma portie vaginalis
uteri, in women [80,81]. The pouch of Douglas, as the lowest point in the abdomen and in the
close vicinity of the rectum, is a place of intraperitoneal spreading of carcinoma of any intra-
abdominal or retroperitoneal organ, with predomination of the stomach and ovarium.
Carcinoma metastasis of retroperitoneal and extra-abdominal organs, pancreas, kidneys and
breast, are described in literature [82,83]. The clinical presentation is similar to those of the
other colon tumors (bleeding, change in the bowel habitus, pain in the region of anus),
supplemented with symptomatology of the primary localization of the malignant process. The
diagnosis implicates anamnesis, digital rectal examination, colonoscopy, endoanal ultrasound,
multi-slice scanner, NMR, as well as, the biopsy with pathohisiological confirmation.
The strategy of treatment depends on:
– localization of the primary malignant process,
– advancement of the disease,
– histological type of the primary tumor
If the primary tumor localization is in the immediate vicinity of the colon and rectum (pancreas,
sigma, prostate, cervix and vagina), it is recommended to use the so called en block resections,
with an aim to achieve the oncological principle of radicalism or R0 procedure [84]. Sometimes,
it is necessary to perform a non-adjuvant therapy in order to reduce the volume of tumor, so
called “downsizing”, and the biological aggressiveness of tumor, “down-staging”, on one
hand, or to supplement the surgical intervention with the adjuvant therapy, on the other. In
the case of extra abdominal localization of the primary tumor, it is necessary to assess the effect
of successfulness of the surgical intervention in achieving a R0 resection, or the application of
the neoadjuvant therapy.
8. Conclusion
Rare tumors of the colon and rectum represent an important group of neoplasms, due to their
specific prognosis secondary to late diagnosis, and resistance to conventional cancer therapy.
Over the last 20 years, their overall incidence has increased, due to advent of novel imaging
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techniques, especially the development of more sophisticated diagnostic tools including high
resolution CT and MRI, capsule endoscopy and somatostatin scintigraphy for NETs. Although
the development of specific targeted therapies such as tyrosine kinase inhibitors for GISTs and
somatostatin analogs for NETs have improved prognosis, early detection remains the critical
variable in determining outcome. Similarly, promising therapeutic data in some subgroups
are encouraging although the majority is still diagnosed late and targeted effective therapy is
lacking. Difference in survival is the consequence of the difference in biological aggressiveness
of tumor, way of the disease spreading and tendency towards metastasis on one hand, and the
frequency of appearance and symptomatology on the other. Carcinoid was an indolent tumor
with the best prognosis, both non-Hodgkin lymphoma and squamous cell carcinoma of the
large bowel showed significantly worse overall survival rate, as compared to adenocarcinoma,
while melanoma has the shortest time of survival. The aim of this chapter is to draw our
attention to the rare tumors in everyday clinical practice.
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